Podcasts about drug administration

What if the reason time feels like it is speeding up has nothing to do with getting older, and everything to do with how you are living? In this episode of Midlife Conversations, we sit down with world-class event coordinator Jessie Schwartzburg for an energizing and practical conversation about taking time to enjoy your time in midlife. Jessie has spent decades designing unforgettable experiences for high-profile clients, bucket-list travel groups, and corporate powerhouses, and her brain works in a way that will genuinely change how you think about your days. We explore why our brains create such vivid memories during new experiences, how small intentional touches can transform an ordinary moment into something people talk about for years, and what it actually takes to stop feeling like life is passing you by. Jessie also breaks down her personal formula for structuring any day or any trip around the four things she believes are the secret to a long, vibrant life: movement, learning, adventure, and connection. You will walk away with practical, immediately actionable ideas, from planning a memorable birthday lunch to finally booking that group trip you have been putting off. This one is a genuine reset for how you are choosing to spend your time in midlife.  

Angela talks to Professor Stuart Philips, who challenges the long-standing "Anabolic Window" myth, revealing that muscle sensitivity to protein actually lasts up to 48 hours post-exercise rather than a mere 30-minute window.  The conversation cuts through the noise of modern protein obsession, establishing that while the RDA is a baseline, the true sweet spot for muscle synthesis lies between 1.2g and 1.6g per kilogram of body weight. WHAT YOU'LL LEARN: The protein "sweet spot": While the baseline requirement is 0.8g/kg, optimal benefits for muscle maintenance and growth occur between 1.2g and 1.6g per kilogram. The myth of the 30-minute window: The "Anabolic Window" is much larger than previously thought; muscles remain sensitive to protein for up to 48 hours after a workout. Dosage limits: For most people, including perimenopausal and postmenopausal women, 30g to 40g of protein per meal is the effective limit for stimulating new muscle growth. Carbohydrates are essential: Despite modern "carb-phobia," carbohydrates are the primary drivers of high-intensity performance TIMESTAMPS [01:50] The confusion between calculating protein [03:52] The "Baking the Cake" analogy [05:54] Debunking the idea that you can only absorb 20g of protein at a time. [07:18] Addressing Anabolic Resistance and protein needs for women in menopause. VALUABLE RESOURCES ⁠Join The High Performance Health Community⁠ ⁠Click here⁠ for discounts on all the products I personally use and recommend A BIG thank you to our sponsors who make the show possible *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. ABOUT THE HOST Angela Foster is an award winning Nutritionist, Health & Performance Coach, Speaker and Host of the High Performance Health podcast. A former Corporate lawyer turned industry leader in biohacking and health optimisation for women, Angela has been featured in various media including Huff Post, Runners world, The Health Optimisation Summit, BrainTap, The Women's Biohacking Conference, Livestrong & Natural Health Magazine. Angela is the creator of BioSyncing®️ a blueprint for ambitious entrepreneurial women to biohack their health so they can 10X how they show up in their business and their family without burning out. CONTACT DETAILS ⁠Instagram⁠ ⁠Facebook⁠ ⁠LinkedIn⁠ Disclaimer: The High Performance Health Podcast is for general information purposes only and do not constitute the practice of professional or coaching advice and no client relationship is formed. The use of information on this podcast, or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for medical or other professional advice, diagnosis, or treatment. Users should seek the assistance of their medical doctor or other health care professional for before taking any steps to implement any of the items discussed in this podcast. This Podcast has been brought to you by Disruptive Media. ⁠https://disruptivemedia.co.uk/

Have you ever left a doctor's appointment with a prescription but still felt like something was missed? If you have Hashimoto's, you are not alone. In this episode, Dr. Aaron Hartman, a triple board-certified physician, breaks down why bad medical advice and Hashimoto's are more connected than most patients realize, and exactly what you can do about it. You will learn: Why medical error affects autoimmune patients more than you think The four root causes behind every autoimmune disease What kind of provider to look for when you feel stuck Hit play to get started.   Episode 129 about LDN with Pharmacist Steve Anderson   Dr. Hartman's book "UnCURABLE - From Hopeless Diagnosis to Defying All Odds"   JOIN THE HEALTH WITH HASHIMOTO'S COMMUNITY Unlock your wellness journey with the free Health with Hashimoto's community! Join a supportive community that's here for you every step of the way. The Health with Hashimoto's community is on Skool: https://www.skool.com/health-with-hashimotos/about   Find all links on my resource page: https://healthwithhashimotos.com/resources/   ABOUT THE PODCAST & ESTHER: The Health with Hashimoto's podcast will help you explore the root causes of your autoimmune condition and discover holistic solutions to address your Hashimoto's thyroiditis. It is hosted by Esther Yunkin, a registered nurse, holistic health educator, and Hashimoto's warrior.   This podcast is for informational and educational purposes. Please discuss any questions or concerns with your healthcare professional. These statements have not been evaluated by the Food and Drug Administration. Products mentioned are not intended to diagnose, treat, cure or prevent any disease.

American officials say they believe China held a nuclear test in 2020, and President Trump reserves the right to do the same, as the New Start arms-control treaty with Russia hits its expiration date this month. Plus, the Food and Drug Administration summarily rejects a flu vaccine from Moderna, before changing course. Learn more about your ad choices. Visit megaphone.fm/adchoices

What if the reason you still feel off (despite trying every diet, supplement, routine, and hormone protocol) is that nobody has ever treated your body as the energy system it actually is? In this conversation, Allison Maslan, who is a classically trained homeopath, founder of Pinnacle Global Network, and a Wall Street Journal bestselling author dives into a conversation that goes far beyond conventional health advice. Allison spent 20 years running her own homeopathic practice, treated thousands of patients, and founded the first homeopathic college in Southern California. She's also in her early 60s, flies trapeze, and is proof that your most powerful chapter can start in midlife. We unpack what homeopathy actually is and why it's been written out of mainstream American medicine, how it can support women navigating menopause and perimenopause (especially those who can't or don't want to use hormones), the science of why your brain literally cannot tell the difference between a vivid visualization and reality, the 1980s study that proved men in their 70s and 80s can physically reverse aging through mindset alone, and Allison's exact Vision Crafting process – the morning ritual she uses to manifest everything from her dream home to business breakthroughs. This episode is for the woman who is tired of only playing defense with her health and is ready to start playing offense with her life with real, science-backed mechanics of how your brain shapes your body and what you can do with that tomorrow morning.  

What really happens when you try to quit sugar — and why perfection isn't required to experience freedom. Episode #246

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I'm just back from MNO DC and I'm exhausted. But it's the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that's our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/     Okay.. our top story this week: XX An "immune system reset" eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells.   After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed.  Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. https://www.thetimes.com/uk/science/article/first-cyborg-pancreas-implants-type-1-diabetes-nxkv8r0fp?gaa_at=eafs&gaa_n=AWEtsqeJYYUF9TMR-GgGUG92hPyog-ISeiqGIgdyaaIKKcpvhtoftGiUaaOtQeG0NWI%3D&gaa_ts=699c50d4&gaa_sig=w-PQ0ArosZSznYDSWEzt8aQg4WC0FF5ZFRt9NedO5sSTL2FyWzupH8eSG7RCy2S8TQnlHOeKCudANWm1MNI59w%3D%3D XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon's drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she's off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act https://lnkd.in/e8pQ7_Y7 XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost hundreds of thousands of dollars. The official Journal of The Transplantation Society estimates the cost at about $140,000. The bill went to the senate committee of Health, Education, Labor, and Pensions in early November. No other action has been taken since then. https://www.wtoc.com/2026/02/19/bluffton-family-advocates-islet-act-help-diabetic-son/ XX Big change for the obesity drug Zepbound – now available in the multi dose KwikPen. This is a month's worth of doses in a single pen.. and it's multi dose – you can adjust it. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. Until now, you could only get zepbound in a single dose auto injector or a sing dose vial. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro – which is the same medication as zepbound, they're both tirzepitide. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html   XX For years, researchers have observed that people who live at high elevations,  tend to develop diabetes less often than those at sea level. Although the trend was well documented, the biological explanation behind it was unclear. Scientists now say they have identified the reason. Their research shows that in low oxygen environments, red blood cells begin absorbing large amounts of glucose from the bloodstream. Their work showed that when oxygen is limited, red blood cells use glucose to generate a molecule that helps release oxygen to tissues. This process becomes especially important when oxygen is in short supply. The researchers also found that the metabolic benefits of prolonged hypoxia lasted for weeks to months after mice were returned to normal oxygen levels. They then evaluated HypoxyStat, a drug recently developed in Jain's lab that mimics low oxygen exposure. HypoxyStat is taken as a pill and works by causing hemoglobin in red blood cells to bind oxygen more tightly, limiting the amount delivered to tissues. In mouse models of diabetes, the medication completely reversed high blood sugar and outperformed existing treatments. https://www.sciencedaily.com/releases/2026/02/260221060952.htm XX Watching this one closely – Portal Diabetes gets FDA breakthrough device designation for its implantable insulin pump system. This is a system that includes not just a device that's implanted into the abdomen, but also a new, temperature stable insulin. It will work with – quote – "modern" CGM technology with a fully closed loop - and aims to deliver a functional cure for type 1. While reports say Portal's system is the first in the US – there was an implantable pump developed and used by about 500 people worldwide, including about 100 in the US – by MiniMed. Medtronic bought the company and in 2007 they stopped that program. Portal Diabetes expects to begin clinical trials on its combination system around the fourth quarter of 2027. https://www.drugdeliverybusiness.com/portal-diabetes-fda-breakthrough-implantable-insulin-pump/ XX Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. That's the eversense cgm and twist pump. Sequel said its full launch with Eversense 365 makes twiist available with two compatible CGMs. twiist also pairs with the Abbott FreeStyle Libre 3 Plus sensor. Eversense 365, an implantable system, rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. https://www.drugdeliverybusiness.com/sequel-senseonics-full-launch-twiist-eversense/ XX Right back with a Dexcom update, and a look at which type of diet reduces insulin use overall.. right after this: -- Back to the news.. Dexcom is watching for expanded Medicare coverage of its continuous glucose monitors to people with Type 2 diabetes who don't take insulin. CEO Jake Leach told investors on Thursday that the company has been "sitting here waiting for a coverage decision" from the Centers for Medicare and Medicaid Services Dexcom started to see commercial coverage unlock for Type 2, non-insulin users toward the end of last year, Leach said. He expects broader Medicare coverage for that group would allow nearly 12 million people to access CGMs.     In the meantime, the American Diabetes Association updated its guidelines last year to recommend clinicians consider using CGMs for Type 2 diabetes when patients are taking glucose-lowering medications other than insulin. Leach said that real world data the company has been generating supports that decision, and that Dexcom has launched a registry for non-insulin users. https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/ XX Medtronic's separation of MiniMed is not yet complete.. but continues to move forward. The company has submitted their next pump – MiniMed Flex – to the FDA. This is a pump smaller than the 780G but uses the same reservoirs and infusion sets. It will also work with both the Simplera Sync and Instinct sensors. Medtronic also began a U.S. pivotal study for Vivera, its third-generation algorithm for automated insulin delivery. It also remains set to submit its MiniMed Fit patch pump system to the FDA by the coming fall. https://www.drugdeliverybusiness.com/medtronic-submits-minimed-flex-fda-q3/ XX A study modelling how genes may influence a child's body mass index over time has found that BMI at age 10 and overall growth rate between ages one and 18 might be important factors, as the two are more likely linked to diabetes, high cholesterol, and heart disease in later life. Nearly 66,000 BMI measurements from around 6,300 children and adolescents aged one to 18 were analysed to understand the role of genes.     "Future research is needed to help identify the most effective ages to prevent obesity or poor growth for long-term benefit." https://www.ndtv.com/health/bmi-at-age-10-growth-rate-up-to-age-18-are-important-factors-for-diabetes-heart-disease-study-11125146 XX A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change. Researchers say the reduced insulin requirement likely reflects improved insulin sensitivity. The original 2024 study reported additional benefits from the vegan diet. Participants lost an average of 11 pounds and showed improvements in insulin sensitivity and glycemic control. Cholesterol levels and kidney function also improved among those following the plant-based plan. https://www.sciencedaily.com/releases/2026/02/260212234212.htm XX Interesting little tidbit from the Winter Olympic Games.. the World Anti-Doping Agency (WADA) was monitoring GLP drug use. An advisory group that makes recommendations about WADA's list of prohibited substances discussed the status of GLP-1 medications, and added semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) to its monitoring program That means patterns of use of these drugs will be tracked both in and out of competition.  The finding will be used to make recommendations about whether GLP-1 agonists should be added to the prohibited list, the spokesperson explained. While GLP-1 drug use is not currently prohibited, that could change before the next Summer Olympic Games in Los Angeles in 2028, he noted. https://www.medpagetoday.com/popmedicine/cultureclinic/119770 XX That's it for in the news!

It has now been one year of the second Trump administration, with many attacks to sexual and reproductive health, rights, and justice aligning entirely with Project 2025's blueprint. Amy Friedrich-Karnik, Director of Federal Policy at the Guttmacher Institute and Anna Bernstein, Principal Federal Policy Advisor at the Guttmacher Institute, sit down to talk with us about the year's assaults on sexual and reproductive health and rights, LGBTQI+ rights, and science and healthcare by the Trump administration. From day one of their return to office, protections for abortion access put in place by the Biden administration were rolled back. This included several protections for privacy, emergency care, and veteran's access. President Trump immediately pardoned anti-abortion activists who had previously violated the FACE (Freedom of Access to Clinic Entrances) Act and has stopped enforcing the act in most places. Anti-science rhetoric increases, with the Food and Drug Administration endorsing junk-science against mifepristone-- one of the drugs used in a medication abortion. To promote mis- and disinformation, data sets, research, and websites were removed from the internet. The passage of the One Big Beautiful Bill Act defunded Planned Parenthood and set work restrictions on Medicaid coverage. Additionally, the administration froze Title X funding, expanded the already-expanded Global Gag Rule, and issued endless attacks to the transgender community.For more information, check out Future Hindsight: https://www.futurehindsight.com/Support the showFollow Us on Social: Twitter: @rePROsFightBack Instagram: @reprosfbFacebook: rePROs Fight Back Bluesky: @reprosfightback.bsky.social Buy rePROs Merch: Bonfire store Email us: jennie@reprosfightback.comRate and Review on Apple PodcastThanks for listening & keep fighting back!

For people living with osteoarthritis, news about potential new treatments often comes with more questions than answers. In this episode of The Health Advocates, we slow things down to explain what it really means when a company submits a New Drug Application, or NDA, to the U.S. Food and Drug Administration. Steven Newmark is joined by Erich Horsley and Dr. Yusuf Yazici from Biosplice Therapeutics to walk through this important regulatory milestone and why it matters for patients. Together, they break down what an NDA is, what happens during FDA review, and what patients should and should not expect while a therapy is under evaluation. The conversation also explores the current osteoarthritis treatment landscape, why progress in this disease has been so challenging, and what researchers mean when they talk about disease-modifying approaches. Contact Our HostSteven Newmark, Chief of Policy at GHLF: snewmark@ghlf.orgA podcast episode produced by Ben Blanc, Director, Digital Production and Engagement at GHLF.We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.orgListen to all episodes of The Health Advocates on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

As global demand for meat grows, this episode of Duke University's Leading Voices in Food podcast examines cell-cultivated protein—real meat grown from animal cells—and the evolving U.S. policy landscape shaping its future. Host Norbert Wilson (Duke World Food Policy Center) speaks with postdoctoral researchers Kate Consavage Stanley (Duke/Bezos Center for Sustainable Proteins) and Katariina Koivusaari (NC State/Bezos Center) about their article in Trends in Food Science and Technology on U.S. regulatory and legislative activity. The conversation explains the joint FDA–USDA regulatory approach for cell-cultivated meat (FDA oversight through cell cultivation; USDA oversight from harvest through processing, packaging, and labeling) and FDA oversight for cell-cultivated seafood (except catfish). They discuss timelines companies report for approval (often two to three years), the lack of federal public guidance on naming and labeling so far, and how USDA label approvals are currently handled case by case (e.g., "cell-cultivated chicken" and "cell-cultivated pork"). The episode also covers state-level labeling laws and the likelihood of federal preemption if state requirements conflict with federal statutes, as well as a growing wave of state restrictions and bans—Florida and Alabama in 2024, followed by Indiana, Mississippi, Montana, Nebraska, and Texas in 2025—plus funding restrictions in South Dakota and Iowa. The guests explore implications for consumers, interstate commerce, innovation, investment, and U.S. leadership, noting ongoing lawsuits in Florida and Texas and continued legislative activity such as a proposed ban in Georgia.   Interview Transcript Kate, let's begin with you. In the paper, you write about the regulatory frameworks that have been developed for cell-cultivated meat and seafood products in the US. To start, let's talk about what's unique about cell-cultivated products from a regulatory standpoint and how the US Department of Agriculture and US Food and Drug Administration have decided to handle cell-cultivated protein products. Kate - Yes, so as you mentioned in the introduction, Norbert, cell-cultivation is a new technology for use of the food supply. So, the US government had to adapt its existing legal frameworks for food safety regulation. As your listeners may already know seafood is regulated by the FDA, so it was within their scope to also regulate cell-cultivated seafood. The FDA therefore regulates all cell-cultivated seafood products with the exception of catfish. When it came to determining the regulatory approach for cell-cultivated products from livestock, poultry, and catfish, it was a bit more nuanced as the processes and components evolved fell under both USDA and FDA purview. In 2019, the FDA and USDA therefore agreed on a joint regulatory approach where the FDA regulates the early stages of the cell cultivation process, including when those cells are taken from the animal, grown in the bioreactor, and matured into specific cell types such as muscle or fat cells. At the point where those cells are ready to be harvested from the bioreactor to use in a food product, oversight transfers to USDA who oversees that harvesting process as well as food processing, packaging, and labeling. I know this joint regulatory approach may sound complicated, but it's important to note that USDA and FDA already coordinate oversight over other foods in the food supply. I'll give you an example that we all love pizza. A frozen cheese pizza is regulated by the FDA, whereas a frozen pizza with meat toppings like pepperoni is regulated by the USDA. It is therefore not unprecedented that FDA and USDA would agree to jointly regulate cell-cultivated products. And while the process is new, the products go through the same safety checks as other foods in the food supply. In the past few years, we've seen four cell-cultivated meat products go through the joint USDA-FDA regulatory process, meaning they can be sold in the US food supply. And one cell-cultivated seafood product has gone through the FDA regulatory process. Kate, thank you for sharing this. And I've used a pizza example in my class, and it is super complex this regulatory maze that we're talking about. It seems like there has been a lot of collaboration between these two agencies, and so that's important to hear. But it is also the case that it seems challenging for cell-cultivated protein companies to get through this process. Is this a fair assessment and would you elaborate? Kate - Yes, absolutely. We've heard from cell-cultivated companies that it can take two to three years to get through this process. And there certainly is a lot of back and forth between the companies and FDA and USDA. Great, thank you. Katariina, now let's turn to you. How do these regulations extend to labeling and what do we know about the federal government's approach to labeling the sale of cultivated products thus far? Katariina – So, labeling regulations are the most consumer facing part of regulations, really. And they are used to ensure that the product label has information that's truthful, that's not misleading. And that the package has sufficient information and consistent information also across products so that the consumer can make an educated decision on what product they want to purchase. And you'd think that how you label the product or just how you call the product on the label would be simple. But there are certain regulations in place that define how food items can or cannot be called. Now, when it comes to cell-cultivated products, as you and Kate mentioned, they are novel in the food supply. So, there is not a long-established term or nomenclature on how we should call these products. The federal regulators, FDA and USDA, to date have not released any public guidance either on how these products should be called on the label. The USDA did release an advanced notice of proposed rulemaking back in 2021, requesting comments from stakeholders on how these products should be labeled. And the FDA has also requested comments when it comes to labeling cell-cultivated fish and seafood. But to date, no guidance has been published yet. Kate gave an overview of the regulatory process between FDA and UFDA when it comes to labeling this product products. The USDA oversees labeling cell-cultivated meat, and the FDA oversees labeling cell-cultivated fish and seafood. The USDA has a pre-market approval process for labels, similarly to conventional meat industry. So, whenever a company wants to bring to market a new product, they first submit their label to the USDA. And the USDA reviews it and make sure that they agree with the language used in the label. The FDA does not have a similar pre-market approval process for labeling fish or seafood or cell-cultivated fish or seafood. So, currently cell-cultivated meat labels are approved on a case-by-case basis. And we can see from the products that have gone through the regulatory review so far that the USDA seem to approve the use of 'cell-cultivated' as a qualifying term, together with a meaty term such as chicken or pork. So, the products that we've seen approved to date or brought to market to date are called cell-cultivated chicken or cell-cultivated pork. This is really helpful to know what's happened at the federal level. We also know that there are several actions happening at the state level, so several states have proposed their own laws outlining how and what to label these products. Katariina, can you talk us through what this study regarding state labeling? Katariina - To date, about half of the US states have enacted or proposed their own labeling legislation on cell-cultivated products. Missouri became the first state in 2018, so well before any of these products was available on the market. And they specifically prohibited the use of word meat unless the food was from harvested production livestock or poultry. Restricting, therefore, the use of meat not only on cell-cultivated, but also on other alternative protein products such as plant-based meat analogs or fermentation derived proteins. And this is true for many state level labeling laws. That they are applicable not only to cell-cultivated meat, but also other alternative proteins aiming to mimic meat. In addition to Missouri, there are six other states that prohibit the use of meat or meat related terms, such as chicken or pork. Now, the other group of states that have restrictions on cell-cultivated meat labeling do not concentrate on prohibiting the use of word meat, but they require the use of qualifying terms or other additional language that clearly states that the product does not come from livestock or poultry. And this group of states, there are 18 states, have quite a bit of variation in what kind of qualifying terms they require to be used. And I thought I'd give a couple of examples here. For example, Indiana requires the package to include the phrase this is an imitation meat product. Iowa requires the product to be labeled with qualifying terms such as cell-cultivated, cell-cultured, fake, grown in a lab, imitation, lab grown, lab created, meat free, or meatless. What's interesting though is that the federal statutes that regulate the US food supply have actual language that prevents states from establishing laws or regulations that conflict with or are additional to the federal labeling regulations. So, this means that the state level labeling laws are actually likely to be preempted if they conflict with the federal regulations. So, we've only talked about labeling so far. Kate, I want to go back to you. More recently, we've seen a number of states propose greater restrictions on these products. Can you describe these attempts to restrict cell-cultivated meat and their immediate implications? And how have cell-cultivated companies and other stakeholders responded? Kate - In the past few years we've seen quite a few attempts by states to ban or restrict cell-cultivated meats. And these attempts fall into two buckets: bans that aim to restrict the manufacturer sale or distribution of cell-cultivated products and bans that aim to limit the use of state funding to support these products. In 2024, Florida was the first state to pass a ban on the manufacture, sale, and distribution of cell-cultivated meats. Alabama followed shortly thereafter. In 2025, five more states passed similar bans on cell-cultivated products, including Indiana, Mississippi, Montana, Nebraska, and Texas. And many other states proposed bans that ultimately didn't pass. The language on what is banned differs some between states. For instance, Texas only bans the sale of cell-cultivated products. Whereas Florida and others also ban cell-cultivated manufacturing and distribution. But the core message in all these bans is similar. Cell-cultivated meats are not welcome in those states. The time span for the bans differs too. So, Indiana and Texas have two-year bans while Florida and other states passed indefinite bans. And we've seen two states, South Dakota and Iowa pass legislation to restrict the use of state funding to support cell-cultivated products. What's frustrating about these bands and confusing for those in the alternative protein sector is that cell-cultivated technology is largely still in the early stages. Yes, as I mentioned earlier, five products have passed through the regulatory process. But these products have mainly been made available in small tasting events. And only one has actually made it to retail. Most Americans have never had a chance to actually try these products. So, it begs the question, why is there such resistance? State bans on these products mean that Americans will not have the chance to decide for themselves if they like these products, or if and how they want to incorporate them into what they eat. Another big concern is that these bans create a fragmented policy landscape that's challenging for cell-cultivated startups, especially, to navigate. And it raises a lot of concerns about cross state sales. Concerns like these are the basis for two lawsuits against cell-cultivated bans in Florida and Texas. Those lawsuits are still playing out in court, so we don't yet know how those may Kate, this is really fascinating. And as both you and Katariina described, there's a patchwork of policies and a complex landscape for these companies to navigate. It has the potential of keeping consumers from even trying the products, as you've already suggested, when they're made available. And what I'm hearing from both of you is that this is an ongoing project. So even though there's a paper that's published now, it seems like there will be opportunities to keep going back as new laws and new regulations and new lawsuits are decided. So, this is a policy space that we need to keep an eye on. That's something I want to pick up on this last question. In closing, what does this legislation mean for consumers and the future of cell-cultivated products in the US and even globally? Katariina, let's begin with you. Katariina - Yes. In addition to impeding interstate and international commerce of cell-cultivated products, these bans could negatively impact the US investment climate on these products and technologies. For example, China has included developing cell-cultivated meat in their five-year plan. Within Europe, there's some variation. Some countries are being rather supportive of these technologies and products, whereas others have tried to ban them similarly to some US states. But I think it's important to note that even with some states in the US banning these products, the US will still likely remain a significant market area for cell-cultivated products. And it still takes significant investment and infrastructure to produce the products on a large scale enough to even reach the whole country. Another really important thing to mention here is that the global demand for meat is growing. If we look at global population forecasts, global meat or protein consumption forecasts, we need these alternative proteins. Not only cell-cultivated meat, but also for example, plant-based meat alternatives to help meet the increasing demand for protein and complement conventional meat supply. Kate, what about you?   Kate – I agree with everything that Katariina said. To add on to her points, I note that the US has been a leader in the cell-cultivated research development and innovation spaces to date. We are one of only a few countries that have both developed a framework for regulating these products and had products successfully pass through that process. The bans tell a different story, and they may restrict US innovation in the cell-cultivated space because companies will be limited to only the states where they can produce and sell these products. What this means for US leadership in the space remains to be seen. However, one could ask will cell-cultivated companies choose to set up shop in the US versus another country that isn't facing such legal challenges? We don't yet know the answer to that. You also mentioned consumers. We don't yet know about how these bans and the media surrounding them may influence consumer perceptions of cell-cultivated foods. Products, as you said, they've never even really had the chance to try. But these bans will certainly restrict consumer access to these products in certain states, and the varying state approaches to labeling that Katariina described are likely to confuse consumers. Going back to something you mentioned earlier, Norbert, we're excited to have this paper out in the world. But this work is certainly continuing to evolve. Just recently, a senator in Georgia proposed a new ban on cell-cultivated meat in the state, and other countries have faced similar legislative challenges against these products. So, we'll be watching and learning as these challenges continue to play out. Bios Katariina Koivusaari, Ph.D. is a postdoctoral researcher at the Bezos Center for Sustainable Protein at North Carolina State University. Her work focuses on stakeholder engagement and the regulatory and policy landscape of alternative proteins, including cell-cultivated products, fermentation-derived proteins, and plant-based proteins. She received her Ph.D. in Public Health Nutrition and M.Sc. in Food Sciences from the University of Helsinki. Prior to her current role, she worked in the biotechnology industry as a Senior Regulatory Scientist, where she focused on scientific strategy and regulatory affairs related to cell-cultured human milk ingredients. Katherine (Kate) Consavage Stanley, Ph.D., serves as a postdoctoral associate within the World Food Policy Center at the Sanford School. In this role, Kate supports Duke's research for the Bezos Center for Sustainable Protein housed at NC State. Her research seeks to detail the complexities of the consumer, market, and policy landscapes for alternative protein products. Kate holds a Ph.D. from Virginia Polytechnic Institute and State University where her research focused on how diverse U.S. food and health systems actors can support sustainable diet transitions through promoting plant-rich dietary patterns and reducing red and processed meat intake. She has also published scholarly work on digital food and nutrition literacy, sugary beverage media campaigns, and incorporating sustainability considerations into dietary guidelines, among others. Prior to starting her doctoral studies, Kate worked for the U.S. Agency for International Development (USAID) where she developed technical, communications, and advocacy-focused materials on key nutrition and maternal and child health issues. Kate holds a Master of Science in global health from Georgetown University and a Bachelor of Science in biology from Emmanuel College.      

About this episode: A recent analysis of FDA documents has found that the agency has historically regulated mifepristone—a medication commonly used to terminate pregnancy—based on available scientific evidence and without ideological bias. In this episode: Caleb Alexander, an author of the study, discusses these findings and their implications for a possible new review of the medication by FDA. Guests: Dr. G. Caleb Alexander, MS, is a practicing internist and drug safety expert at the Johns Hopkins Bloomberg School of Public Health. Host: Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health. Show links and related content: The US Food and Drug Administration's Regulation of Mifepristone—JAMA Study: FDA Regulation of Abortion Drug Mifepristone from 2011 to 2023 Shaped by Evidence and Caution—Johns Hopkins Bloomberg School of Public Health F.D.A. Decisions on Abortion Pill Were Based on Science, New Analysis Finds—New York Times What Is Mifepristone, aka "The Abortion Pill"?—Johns Hopkins Bloomberg School of Public Health What's at Stake for Access to Medication Abortion and the FDA in the Supreme Court Case FDA v. the Alliance for Hippocratic Medicine?—KFF Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Hey Mama,  Do you want to learn how to find time to exercise as a busy mom? Studies show moving your body is not only essential for your physical health, but also for your mental health. As moms, it can be difficult to find the time to exercise with all of the responsibilities we have.  Maybe you know exercise is good for you, but you are not sure where to start. Maybe you desire to be active like you used to, but your body is different, and you can't do what you used to.  No matter your age and stage, Mama, you can move your body and you should move your body because movement improves your mental health. Your mental health matters, for you and your family. Join me today as I share with you three practical tips to make time for exercise as a busy mom.   For His Glory, Christen   I would love to hear from you!  >>Leave a Review >>Connect with me:   Sign Up for Manage In The Moment Coaching Call: https://bit.ly/ManageStressInTheMoment   Email me : naturalwellnessforbusymoms@gmail.com  Sign Up to Become an Insider: https://bit.ly/naturalwellnessinsider  Join Our FREE Facebook Community:https://www.facebook.com/groups/1789472588229094  >>Find Related Products Here: https://bit.ly/m/Natural-Wellness-for-Busy-Moms  >> These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. >>I make a small commission when using the links above to purchase items.

The Food and Drug Administration will review Moderna's new flu vaccine after reversing course. Medicare Advantage growth in 2026 is trailing prior years. And Amazon is expanding same-day prescription delivery to nearly 5,000 cities nationwide. Those stories and more on today's episode of The Gist Healthcare Podcast. Hosted on Acast. See acast.com/privacy for more information.

Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman, Senior Editor Sue Sutter, and Editor-in-Chief Nielsen Hobbs discuss a series of US Food and Drug Administration proposals for user fee program changes that would advance President Trump's priorities and the concerns they raise (:31). They also consider the impact of the agency's decision to review Moderna's mRNA flu vaccine application shortly after refusing to file it and using accelerated approval for one of the proposed indications (8:37), as well as ideas for sponsors wondering if their development advice is still good (25:24). More On These Topics From The Pink Sheet US FDA Proposing White House-Aligned Policies For User Fee Agreements: https://insights.citeline.com/pink-sheet/pathways-and-standards/user-fees/us-fda-proposing-white-house-aligned-policies-for-user-fee-agreements-D5JWRDGLCFBT7CYT3FGK3JAZNI/ After Moderna Flu Vaccine, Is US FDA's Accelerated Approval A Pathway Or A Pressure Valve?: https://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/after-moderna-flu-vaccine-is-us-fdas-accelerated-approval-a-pathway-or-a-pressure-valve-EWMFKFWO3BB3JA6CQHC4E3JWPA/ Moderna Flu Vaccine Debate Could Resolve With Postmarket Study, FDA's Makary Suggests: https://insights.citeline.com/pink-sheet/vaccines/moderna-flu-vaccine-debate-could-resolve-with-postmarket-study-makary-suggests-Y3R657N2JZABRGFOSKADM33YA4/ Horse Trading? Oz, Bourla Exchange MFN Codification, Vaccine Collaboration Requests: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/horse-trading-oz-bourla-exchange-mfn-codification-vaccine-collaboration-requests-X6UDDVOSMRBSTO5WC224IN6PTE/

Today's Headlines: Billionaire retail mogul Les Wexner testified before Congress about his ties to Jeffrey Epstein — but instead of appearing on Capitol Hill, lawmakers traveled to his Ohio mansion, where the 88-year-old was deposed with family members present. Notably, no Republicans on the House Oversight Committee showed up. Wexner, who once granted Epstein power of attorney, said he was “naive, gullible, and foolish” and claimed he was conned, despite building a multibillion-dollar empire. It wasn't the only billionaire hot seat of the day. Mark Zuckerberg testified in a landmark trial against Meta over allegations the company knowingly made its platforms addictive and harmful to children. The case could influence more than 1,500 pending social media addiction lawsuits. Meanwhile, The New York Times reported Meta has set aside $65 million to back state-level politicians friendly to the AI industry through new super PACs in Illinois and Texas — timing that feels… strategic. In federal agency cleanup news, the U.S. Food and Drug Administration removed a webpage warning against bogus autism “treatments” like chlorine dioxide and raw camel milk, calling it routine housekeeping. On the foreign policy front, Donald Trump met with advisers to discuss Iran, as mixed signals emerge from nuclear talks in Geneva and two U.S. aircraft carriers sit in the Mediterranean. The administration also plans to withdraw roughly 1,000 U.S. troops from Syria over the next two months, though officials say the move is “conditions based.” Meanwhile, a potential U.S. arms sale to Taiwan is reportedly in limbo ahead of Trump's planned meeting with Xi Jinping in Beijing. Back home, New York City Mayor Zohran Mamdani announced the city will resume clearing homeless encampments following at least 19 deaths during a recent cold snap, with outreach led by homeless services rather than police. Resources/Articles mentioned in this episode: AP News: Billionaire Les Wexner says he was 'duped' by adviser Jeffrey Epstein, 'a world-class con man' Axios: Zuckerberg testifies in landmark social media addiction trial NYT: Meta Begins $65 Million Election Push to Advance A.I. Agenda ProPublica: Chlorine Dioxide, Raw Camel Milk: The FDA No Longer Warns Against These and Other Ineffective Autism Treatments Axios: Trump meets with top Iran advisers as war threat grows WSJ: U.S. Is Withdrawing All Forces From Syria, Officials Say WSJ: U.S. Arms Sale to Taiwan in Limbo Amid Pressure Campaign From China AP News: Mamdani reboots homeless encampment sweeps in New York City Subscribe to the Betches News Room and join the Morning Announcements group chat. Go to: ⁠⁠⁠betchesnews.substack.com Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

The twists and turns continue at the nation's health agency, where this week's announcements included notice that the Food and Drug Administration will review Moderna's new flu vaccine after all and that a handful of top agency officials are getting new jobs.Those developments and others can be traced to a White House looking to shake things up before the midterms — and win over voters on health care. Tami Luhby of CNN, Shefali Luthra of The 19th, and Lauren Weber of The Washington Post join KFF Health News' Mary Agnes Carey to discuss these stories and more. Visit our website for a transcript of this episode.Plus, for “extra credit” the panelists suggest health policy stories they read this week that they think you should read, too:  Mary Agnes Carey: Politico's “Why Congress Failed To Reach an Obamacare Deal,” by Robert King and Simon J. Levien. Lauren Weber: NiemanLab's “The Atlantic's Elizabeth Bruenig on Her ‘Hypothetical,' Heavily Reported Measles Essay,” by Laura Hazard Owen. Tami Luhby: The City's “NewYork-Presbyterian Nurses Reject Contract by Overwhelming Margin,” by Claudia Irizarry Aponte and Ben Fractenberg. Shefali Luthra: NPR's “Minneapolis Doctors Warn of Lasting Medical Effects, Even After ICE Agents Leave,” by Jasmine Garsd. 

It's Thursday, February 19th, A.D. 2026. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Jonathan Clark British preacher challenges buffer zones around abortion mills A preacher in Britain is challenging the country's abortion buffer zones which effectively censor the Bible. Officials arrested, charged, and convicted Stephen Green for holding a sign with a Bible verse near an abortion mill in 2023. The verse was Psalm 139:13 which says, “For You formed my inward parts; You knitted me together in my mother's womb.” Green stated, “As a Christian, I should be able to preach freely all over the land. Psalm 139 is about how we all belong to God from conception. Buffer zones and this conviction [are] a direct attack on the Bible and free speech.” Elon Musk endorsed new conservative political party in England Billionaire Elon Musk endorsed a new conservative political party in Britain last week. On Friday, Member of Parliament Rupert Lowe launched the Restore Britain Party. Musk shared the launch video on X which has received nearly 40 million views.  The party is devoted to ending mass immigration and the creeping Islamification of Britain. Rupert Lowe also stated the party will openly recognize the country's Christian heritage.  Listen. LOWE: “Restore Britain will openly recognize the Christian heritage that shaped this country's moral and civic foundation. (applause) Duty, restraint, forgiveness and, most importantly, fairness. These values created a high trust society. “Restore Britain will end the creeping Islamification of Britain. (applause)  Unfettered immigration from Islamic countries will end. (applause) Britain is a Christian country, and under Restore Britain government, it will remain a Christian country.” (applause) Church of England votes against blessing homosexual couples Last week, the Church of England  voted against proposals to allow blessing services for homosexual couples. The General Synod did not shut the door on the issue though, voting to investigate it in the future.  The move keeps the church from performing marriage services and blessing services for people living in unnatural relations. However, the Church of England's rules already allow blessing prayers within regular Sunday services for such couples.  Proverbs 25:26 says, “Like a muddied spring or a polluted fountain is a righteous man who gives way before the wicked.” Franklin Graham preached in world's southernmost city Evangelist Franklin Graham  preached in Ushuaia, Argentina. It's known as the southernmost city in the world. Listen. GRAHAM: “What makes Ushuaia so special are the people. We love the people. If you can't remember anything else tonight, remember this: God loves you. God sent His Son, Jesus Christ, to take our sins. We deserve death. We're guilty of sin. “Bartimaeus had no hope. There are many of you here tonight. You have no hope. Now, Bartimaeus cried at the right time. Jesus was passing by. The Bible says that ‘God so loved the world that He gave His only begotten Son that whosoever believeth in Him should not perish, but he should have everlasting life.' “Will you invite Christ into your heart? Will you trust Him? Come. Come to Jesus.” Hundreds of people turned to Christ through the evangelistic outreach event. Graham wrote on X, “We give God the glory for each one who responded to the invitation to repent of their sins and put their trust in Jesus Christ as their Lord and Savior.” Eighty-two percent of South Americans identify as Roman Catholic, but evangelicalism has been growing in recent decades.    Graham also plans to visit Peru next month. 21 states challenge mail-order abortion kill pills In the United States, 21 states and 60 members of Congress are challenging mail-order abortion drugs. Louisiana initiated the case, challenging a Biden-era rule from the U.S. Food and Drug Administration. The rule removed the in-person dispensing requirement for the abortion drug mifepristone.  Erik Baptist with Alliance Defending Freedom stated, “The Biden FDA's unlawful authorization of mail-order abortion drugs was meant to be a loophole around states that choose to protect life.” 41-year-old mother Olympic bobsledder wins gold (audio Olympic theme song) American Olympic bobsledder Elana Meyers Taylor  won her first gold medal on Monday. The 41-year-old mother triumphed in the women's monobob event at the 2026 Winter Olympics in Italy.  She is now the oldest gold medalist in an individual Olympic event. After the victory, she said this on Instagram: “The moment we prayed for. Glory to God.” Norway has won the most gold medals Nearly 2,900 athletes from over 90 countries are competing in the 2026 Winter Olympics.  So far, Norway has won the most gold medals and the most medals overall. In the medal count, Norway is followed by Italy and the U.S. A podium finish can mean big prize money for athletes. A gold medalist from the U.S. can win $38,000. Athletes from Singapore can make the most for winning an individual event at $792,000.   Christian missionaries sharing Christ & Bibles in Olympic crowds And finally, Evangelicals are sharing the Gospel at the Winter Olympic Games this year. Hundreds of Southern Baptists alongside International Mission Board missionaries are joining the crowds to share Christ and distribute Bibles. Karen Herfurth is in Italy with a group from Mt. Zion Baptist Church in Huntsville, Alabama. She said, “This is a chance for Southern Baptists to reach more people and impact more lives! We may never know the difference this makes until we are in Heaven.” Close And that's The Worldview on this Thursday, February 19th, in the year of our Lord 2026. Follow us on X or subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com.  Plus, you can get the Generations app through Google Play or The App Store. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

Tired of thyroid meds eating into your budget every month? You're not stuck with high prices—especially with Hashimoto's or hypothyroidism. This episode breaks down three real options to how to save money on thyroid medication so you can stay consistent with your levothyroxine (or other thyroid needs) without the stress. The core message: A quick comparison puts you back in control as the CEO of your health. You'll discover: How GoodRx coupons stack up against Cost Plus Drugs' transparent generics and TrumpRx's brand discounts (with actual price examples for common doses). Why generics often win on cost, but sticking to one manufacturer matters for feeling stable. How to pick the best fit for your life—local pharmacy loyalty, mail-order ease, cash vs. insurance, or whatever season you're in. No overwhelm, just practical RN advice (including my small-town pharmacy wins). Hit play and check prices on your next refill—you've got this!   Links: TrumpRx - https://trumprx.gov  GoodRx - https://www.goodrx.com  Cost Plus Drugs - https://www.costplusdrugs.com    JOIN THE HEALTH WITH HASHIMOTO'S COMMUNITY Unlock your wellness journey with the free Health with Hashimoto's community! Join a supportive community that's here for you every step of the way. The Health with Hashimoto's community is on Skool: https://www.skool.com/health-with-hashimotos/about   Find all links on my resource page: https://healthwithhashimotos.com/resources/   ABOUT THE PODCAST & ESTHER: The Health with Hashimoto's podcast will help you explore the root causes of your autoimmune condition and discover holistic solutions to address your Hashimoto's thyroiditis. It is hosted by Esther Yunkin, a registered nurse, holistic health educator, and Hashimoto's warrior.   This podcast is for informational and educational purposes. Please discuss any questions or concerns with your healthcare professional. These statements have not been evaluated by the Food and Drug Administration. Products mentioned are not intended to diagnose, treat, cure or prevent any disease.

The Food and Drug Administration agreed to begin a review of biotech company Moderna's application to make a new seasonal flu shot available. The decision comes after the FDA initially refused to review the company's application. It's a back and forth that reveals increased turmoil within the agency. WSJ's Liz Essley Whyte takes us inside the FDA's unexpected reversals and explores what's next for the mRNA flu vaccine. Jessica Mendoza hosts.  Further Listening: - The FDA Commissioner on Vaccines and Public Trust - Breakfast Battle: The Cereal Industry vs MAHA Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

A partial government shutdown is impacting the Department of Homeland Security, leaving essential personnel to work without pay as Republicans and Democrats remain divided over funding. The debate intensified following controversial immigration enforcement actions in Minneapolis & Los Angeles that have sparked anti-ICE protests and demands for stricter oversight of federal agents. Rep.Tony Gonzales (R-TX), whose district covers 800 miles of the southern border, joins to discuss the DHS funding standoff, the focus on the removal of criminal illegal aliens, and why he believes the border is more secure now than under the previous administration.The Trump administration is once again taking a closer look at the American diet and what's in it. As part of the Department of Health and Human Services “Make America Healthy Again” agenda, the Food and Drug Administration is targeting the longstanding “Generally Recognized as Safe” (GRAS) rule, which allows food companies to self-certify ingredients without federal oversight. FDA Deputy Commissioner for Human Foods Kyle Diamantas joins the Rundown to discuss how Americans can avoid potentially harmful processed ingredients and the steps Washington is taking to eliminate them. Plus, commentary by FOX News Contributor, Richard Fowler. Learn more about your ad choices. Visit podcastchoices.com/adchoices

A partial government shutdown is impacting the Department of Homeland Security, leaving essential personnel to work without pay as Republicans and Democrats remain divided over funding. The debate intensified following controversial immigration enforcement actions in Minneapolis & Los Angeles that have sparked anti-ICE protests and demands for stricter oversight of federal agents. Rep.Tony Gonzales (R-TX), whose district covers 800 miles of the southern border, joins to discuss the DHS funding standoff, the focus on the removal of criminal illegal aliens, and why he believes the border is more secure now than under the previous administration.The Trump administration is once again taking a closer look at the American diet and what's in it. As part of the Department of Health and Human Services “Make America Healthy Again” agenda, the Food and Drug Administration is targeting the longstanding “Generally Recognized as Safe” (GRAS) rule, which allows food companies to self-certify ingredients without federal oversight. FDA Deputy Commissioner for Human Foods Kyle Diamantas joins the Rundown to discuss how Americans can avoid potentially harmful processed ingredients and the steps Washington is taking to eliminate them. Plus, commentary by FOX News Contributor, Richard Fowler. Learn more about your ad choices. Visit podcastchoices.com/adchoices

A partial government shutdown is impacting the Department of Homeland Security, leaving essential personnel to work without pay as Republicans and Democrats remain divided over funding. The debate intensified following controversial immigration enforcement actions in Minneapolis & Los Angeles that have sparked anti-ICE protests and demands for stricter oversight of federal agents. Rep.Tony Gonzales (R-TX), whose district covers 800 miles of the southern border, joins to discuss the DHS funding standoff, the focus on the removal of criminal illegal aliens, and why he believes the border is more secure now than under the previous administration.The Trump administration is once again taking a closer look at the American diet and what's in it. As part of the Department of Health and Human Services “Make America Healthy Again” agenda, the Food and Drug Administration is targeting the longstanding “Generally Recognized as Safe” (GRAS) rule, which allows food companies to self-certify ingredients without federal oversight. FDA Deputy Commissioner for Human Foods Kyle Diamantas joins the Rundown to discuss how Americans can avoid potentially harmful processed ingredients and the steps Washington is taking to eliminate them. Plus, commentary by FOX News Contributor, Richard Fowler. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In 1980, toxic shock syndrome (TSS) emerged as a public health crisis among women who used tampons. There were hundreds of cases, and The Centers for Disease Control linked deaths from TSS to super-absorbent tampons.The Food and Drug Administration responded by assembling a ‘Tampon Task Force' in 1982 to develop safety standards. A researcher called Nancy King Reame was recruited to run the independent laboratory testing. Her work helped establish the first national absorbency standards for tampons. Golda Arthur speaks to Nancy King Reame. Eye-witness accounts brought to life by archive. Witness History is for those fascinated by the past. We take you to the events that have shaped our world through the eyes of the people who were there. For nine minutes every day, we take you back in time and all over the world, to examine wars, coups, scientific discoveries, cultural moments and much more. Recent episodes explore everything from the death of Adolf Hitler, the first spacewalk and the making of the movie Jaws, to celebrity tortoise Lonesome George, the Kobe earthquake and the invention of superglue. We look at the lives of some of the most famous leaders, artists, scientists and personalities in history, including: Eva Peron – Argentina's Evita; President Ronald Reagan and his famous ‘tear down this wall' speech; Thomas Keneally on why he wrote Schindler's List; and Jacques Derrida, France's ‘rock star' philosopher. You can learn all about fascinating and surprising stories, such as the civil rights swimming protest; the disastrous D-Day rehearsal; and the death of one of the world's oldest languages.(Photo: Tampons. Credit: Getty Images)

What if everything the government told you to eat for 30 years was literally backwards? If you're over 45 and you've been confused by decades of conflicting nutrition advice, this conversation is for you. You've been told to eat fat-free and then full-fat. You've been told carbs are evil and then that you need them. The food pyramid told us to load up on bread, pasta, and rice while keeping fat to a bare minimum. We followed that advice. And we got fatter, sicker, and more inflamed than ever. Now the entire framework has been flipped upside down.  This isn't your fault. The recommendations actually were wrong, and they're finally correcting course. Nutrition has somehow become political. The real reason the old food pyramid was designed the way it was has nothing to do with what's actually healthy for your body. Spoiler alert: it was about fear of fat, preventing deficiency, and keeping people fed cheaply. Optimization? That wasn't even on the radar. In this episode, Natalie sits down with registered dietitian Keri Glassman to break down the 2025 dietary guidelines, how the government's shift from "preventing disease" to "supporting optimal health" changes literally everything about nutrition that we've seen for decades, the specifics that the new guidelines finally got right (and the nuances they still missed), the seed oil debate and what actually matters, how GP1's are becoming genuinely life-changing for some women, and why the glamorization of eating disorders on social media connected to these drugs is deeply concerning…and more!  But understanding what changed is only half the battle. The bigger conversation is about learning to trust your own body's signals, understanding that your nutrition needs over 45 are different than at 25, and finding what actually works for YOUR individual situation instead of following yet another set of rules.   Catch the full episode on YOUTUBE HERE: https://bit.ly/MidlifeConversationsYouTube    Learn More About Keri Glassman Instagram ➜ https://www.instagram.com/keriglassman  Website ➜  https://nutritiouslife.com/  Thank you to our show sponsors! BIOPTIMIZERS: Get the digestive enzymes I take with every meal here https://www.bioptimizers.com/nataliejill  Free Gifts for being a listener of Midlife Conversations! Mastering the Midlife Midsection Guide: https://theflatbellyguide.com/ Age Optimizing and Supplement Guide: https://ageoptimizer.com   Connect with me on social media! Instagram: www.Instagram.com/Nataliejllfit Facebook: www.Facebook.com/Nataliejillfit   For advertising inquiries: https://www.category3.ca/  Disclaimer: Information provided in the Midlife Conversations podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before making any changes to your current regimen.  Information provided in this podcast and the use of any products or services related to this podcast does not create a client-patient relationship between you and the host of Midlife Conversations or you and any doctor or provider interviewed and featured on this show. Information and statements may have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease. Advertising Disclosure: Some episodes of Midlife Conversations may be sponsored by products or services discussed during the show. The host may receive compensation for such advertisements or if you purchase products through affiliate links. Opinions expressed about products or services are those of the host and/or guests and do not necessarily reflect the views of any sponsor. Sponsorship does not imply endorsement of any product or service by healthcare professionals featured on this podcast.  

The U.S. Food and Drug Administration announced recently that it will not review Moderna's mRNA flu vaccine, despite late-stage trials showing it was safe and effective. The rejection has many in and outside the industry concerned about the Trump administration's approach to vaccine development and recommendations. Amna Nawaz discussed more with Michael Osterholm. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Why shorter fasts often stop working once insulin resistance is established — and what therapeutic fasting is actually designed to do. Episode #245

Hey Mama,  Over the past couple weeks, I have talked with you about the importance of hydration for your physical and mental wellbeing. Not only does hydration improve your body's ability to receive and manage stress well, but it is essential to living a vibrant life.  Last week, I shared with you practical ways to incorporate more water into your day, even as a busy mom. Today, I want to share with you the ultimate water you need to combat stress, anxiety and overstimulation as a mom.   For His Glory, Christen   I would love to hear from you!  >>Leave a Review >>Connect with me:   Sign Up for Manage In The Moment Coaching Call: https://bit.ly/ManageStressInTheMoment   Email me : naturalwellnessforbusymoms@gmail.com  Sign Up to Become an Insider: https://bit.ly/naturalwellnessinsider  Join Our FREE Facebook Community:https://www.facebook.com/groups/1789472588229094  >>Find Related Products Here: https://bit.ly/m/Natural-Wellness-for-Busy-Moms  >> These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. >>I make a small commission when using the links above to purchase items.

Angela talks to Ari Whitten, the founder of The Energy Blueprint and an expert in mitochondrial health about his comprehensive approach to overcoming fatigue and optimising energy levels by addressing the cellular engines of the body—the mitochondria.  Ari explains how modern lifestyle factors, such as poor light exposure, chronic stress, and nutritional deficiencies, signal the mitochondria to enter a defence mode rather than an energy-producing mode WHAT YOU'LL LEARN: The Cell Danger Response (CDR): Mitochondria have a dual role; they are not just energy producers but also environmental sensors that shift into a defensive state when they perceive threats Circadian Rhythm and Light: Proper exposure to natural light in the morning and minimising artificial blue light at night is critical for regulating the mitochondrial clock and ensuring deep, restorative sleep. Hormetic Stress: Introducing controlled stressors—such as high-intensity exercise, cold exposure, or heat—can actually strengthen mitochondria and increase their capacity to produce energy The Importance of Nutrient Density: Specific nutrients, including CoQ10, magnesium, and polyphenols, are essential "fuel" for the electron transport chain TIMESTAMPS [00:04:15] The "Energy Gap" [00:18:30] Mitochondria as Sensors [00:32:45] The Power of Red Light Therapy [00:52:10] Building Metabolic Flexibility VALUABLE RESOURCES ⁠Join The High Performance Health Community⁠ ⁠Click here⁠ for discounts on all the products I personally use and recommend A BIG thank you to our sponsors who make the show possible The Ultimate Guide to Red Light Therapy  Find out your biological age and how your daily habits are influencing it with DNA, bloodwork and microbiome testing with a Stride One membership - visit https://www.getstride.com/angela/ for 10% off. Ready to support your body at the cellular level where it matters? Head to www.MitoQ.com and use my code ANGELA for 10% off your first order *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. ABOUT THE HOST Angela Foster is an award winning Nutritionist, Health & Performance Coach, Speaker and Host of the High Performance Health podcast. A former Corporate lawyer turned industry leader in biohacking and health optimisation for women, Angela has been featured in various media including Huff Post, Runners world, The Health Optimisation Summit, BrainTap, The Women's Biohacking Conference, Livestrong & Natural Health Magazine. Angela is the creator of BioSyncing®️ a blueprint for ambitious entrepreneurial women to biohack their health so they can 10X how they show up in their business and their family without burning out. CONTACT DETAILS ⁠Instagram⁠ ⁠Facebook⁠ ⁠LinkedIn⁠ Disclaimer: The High Performance Health Podcast is for general information purposes only and do not constitute the practice of professional or coaching advice and no client relationship is formed. The use of information on this podcast, or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for medical or other professional advice, diagnosis, or treatment. Users should seek the assistance of their medical doctor or other health care professional for before taking any steps to implement any of the items discussed in this podcast. This Podcast has been brought to you by Disruptive Media. ⁠https://disruptivemedia.co.uk/

In this episode, I'm sharing a recent YouTube Live where I answer questions regarding overcoming an iron deficiency. Fatigue, lethargy, depression, anxiety, lack of motivation, under performing, shortness of breath, palpitations, feeling cold all the time. These can all be symptoms of low iron.* Download the Optimize Iron Guide Check out Blood Vitality *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Ask your lifestyle health questions on social media, tag @drwholeness and use #accumulatehealth. -------- Connect with Dr. Matt online:

Guest Full Name: Dr. R. Stacy Lindborg, PhDGuest Title: President, Chief Executive Officer, and Board DirectorCompany: IMUNONTicker: IMNNWebsite: https://imunon.com/Guest Bio:Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of IMUNON in May 2024. Dr. Lindborg has served on IMUNON's Board of Directors since June 2021. She has nearly 30 years of experience in the pharmaceutical and biotech industries, with a particular focus on R&D, regulatory affairs, executive management, and strategy development. She has designed, hired, and led global teams, guiding long-term visions for growth through analytics and stimulating innovative development platforms to increase productivity.Prior to joining IMUNON, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics, where she remains a member of the company's Board of Directors. At BrainStorm, she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She frequently interacted with investors and analysts, represented the company in the scientific community and with the media, and played an active role in discussions with potential business partners.Dr. Lindborg previously was Vice President and Head of Global Analytics and Data Sciences, responsible for R&D and marketed products at Biogen. She began her biopharmaceutical career at Eli Lilly and Company, where, over the course of 16 years, she assumed positions of increasing responsibility, including Head of R&D strategy.Dr. Lindborg received an MA and PhD in statistics, and a BA in psychology and math from Baylor University. She has authored more than 200 presentations and 90 manuscripts that have been published in peer-reviewed journals, including 20 first-authored. She has held numerous positions within the International Biometric Society and American Statistical Association and was elected Fellow in 2008.Company Bio:IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of diseases. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.IMUNON's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. IMNN-001 is the first therapy to achieve a clinically effective response in advanced (stage IIIC/IV) ovarian cancer including benefits in both progression-free survival (PFS) and overall survival (OS) in a first-line treatment setting when used with standard of care chemotherapy. IMUNON has completed multiple clinical trials evaluating the potential of IMNN-001, including one Phase 2 clinical trial (OVATION 2), and is currently conducting a Phase 3 clinical trial (OVATION 3). The first patient was dosed in the Phase 3 study in the third quarter of 2025. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as IL-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the US Food and Drug Administration's controversial decision to refuse to file Moderna's mRNA-1010 seasonal influenza vaccine candidate, including the unusual public airing of grievances (2:10), the changing issues sparking RTF actions (5:51), the uncertainty created by the decision and how vaccine sponsors should react going forward (16:54). More On These Topics From The Pink Sheet Moderna Cites Changing Advice As US FDA Refuses To File Flu Vaccine BLA: https://insights.citeline.com/pink-sheet/vaccines/moderna-cites-changing-advice-as-us-fda-refuses-to-file-flu-vaccine-bla-SRLIEHHMOFEWFPTLYJCXFIF5FM/ HHS Defends US FDA Refusal To File Moderna's Flu Vaccine: https://insights.citeline.com/pink-sheet/vaccines/hhs-defends-us-fda-refusal-to-file-modernas-flu-vaccine-NULTQ6P6R5C6DDXZFMZROE3HRU/

It's been a busy week at the Food and Drug Administration, with a political appointee overruling agency scientists to reject an application for a new flu vaccine, a decision that's reverberating through the drug industry. Meanwhile, anti-abortion Republicans on Capitol Hill complain the agency is dragging its feet on reviewing the abortion pill mifepristone. Alice Miranda Ollstein of Politico, Lizzy Lawrence of Stat, and Jackie Fortiér of KFF Health News join KFF Health News' Julie Rovner. Plus, for “extra credit” the panelists suggest health policy stories they read this week that they think you should read, too: Julie Rovner: ProPublica's “The Children of Dilley,” by Mica Rosenberg.  Alice Miranda Ollstein: Politico's “Why Washington's All-In on Smart Rings,” by Amanda Chu.  Lizzy Lawrence: KFF Health News' “US Cancer Institute Studying Ivermectin's ‘Ability To Kill Cancer Cells,'” by Rachana Pradhan.  Jackie Fortiér: Stat's “The New Childhood Vaccine Guidelines Have a Paid Leave Problem,” by Ariana Hendrix.  

It's Thursday, February 12th, A.D. 2026. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Jonathan Clark Olympics can prompt prayer among Christian viewers (Audio of Olympic theme song) Over 3,500 athletes from 93 countries are competing at the 2026 Winter Olympics Games in Milan, Italy this month. Fourteen of these countries are on the Open Doors' World Watch List of the most oppressive places to be a Christian. Those countries include Eritrea, Nigeria, Pakistan, Iran, India, and China.  Open Doors has a message for Christian viewers of the Olympics. They said, “Use the Olympics in a potentially surprising way: to pray.  … Take a moment to think about the situation of your brothers and sisters in that country and pray for it.” You can reference the organization's prayer guide for each country through a link in our transcript today at TheWorldview.com.  Ephesians 6:18 says, “Pray at all times in the Spirit with every prayer and request, and stay alert with all perseverance and intercession for all the saints.” Canadian gunman killed 10 people at school Tragically, a transgender shooter opened fire at a Canadian school on Tuesday, reports LifeSiteNews.com. Jesse Strang, a 17-year-old male pretending to be a female while wearing a dress, reportedly killed 10 people including himself.  He also injured 25 people. It's Canada's deadliest school shooting in decades.   The shooting took place at Tumbler Ridge Secondary School in northeastern British Columbia which has fewer than 200 students enrolled in Grades 7 through 12. Chris Elston, a Canadian pro-family activist, said, “He was a young man who needed serious help for his mental health. Instead, his delusion was affirmed, and the result is murdered innocent children.” Later, Elston added, “Someone needed to tell this kid the truth and help him to be happy as a man, but it's illegal to do so. It's a criminal offense of conversion therapy. So, he never got help and he got worse. Murdered children paid the price for our politicians' stupidity and cowardice. Not even our police can call him a man. A cult has taken over our society. “ Please pray for the families suffering through this unimaginable loss. YouVersion Bible engagement up dramatically in Latin America Online Bible platforms are seeing unprecedented engagement in Latin America so far this year. This trend marks a year since the YouVersion Bible platform established a regional office in Mexico City. On January 1, nearly two million people subscribed to Bible reading plans. And the app saw over 22.2 million active users on the first Sunday of the year. This marks a 20% growth from last year. Countries with record levels of engagement include Mexico, Colombia, Argentina, and El Salvador.   Only 31% o Protestants read Bible daily In the United States, new analysis from Lifeway Research found most Protestant churchgoers don't read the Bible on a daily basis. Seventeen percent of churchgoers read the Bible at least monthly. Fourteen percent read weekly. Thirty percent read a few times a week. And only 31% read the Bible daily. However, the percentage of churchgoers who read the Bible daily or at least a few times a week is now 61%. That's up from 36% in 2007. Romans 12:2 reminds us, “Do not be conformed to this world, but be transformed by the renewing of your mind, that you may prove what is that good and acceptable and perfect will of God.” GOP to FDA: Abortion Kill Pill is hurting women U.S. Senate Republicans criticized the Food and Drug Administration on Tuesday after a closed-door briefing on the abortion kill pill. The FDA is supposed to be conducting a safety review of mifepristone, one of the drugs used in chemical abortions. Republicans are accusing the agency of dragging its feet on the study. Listen to comments from Republican Senator Josh Hawley of Missouri in an interview on Washington Watch with Tony Perkins of the Family Research Council. HAWLEY: “Tony. I just think, at this point, this study, it's vital. It should be done. I don't have any confidence that the FDA is actually going to do it. And, in the meantime, abortions in this country are increasing. There are more abortions now than when Roe was the law of the land. And that's because of this chemical abortion.” U.S. homicides down 20% The Major Cities Chiefs Association released its latest report on violent crime in the U.S. The report collects data from 67 of America's biggest police departments. Compared to 2024, reported homicides were down nearly 20% last year. And reported violent crimes are falling after a surge of reports during the COVID-era shutdowns. 130,000 new American jobs The United States added 130,000 jobs in January, according to the Bureau of Labor Statistics. Analysts expected only 55,000 jobs. It's the biggest job growth in over a year. The gains were led by healthcare, social assistance, and construction.  The unemployment rate remained slightly elevated at 4.3%. 92% of Americans like religious themes in movies & TV And finally, a new survey found most Americans are open to religious themes in movies and TV shows. The 2026 Faith & Entertainment Index found 92% of U.S. adults say faith has a role to play in modern entertainment. And 77% believe it can have broad appeal. Brooke Zaugg, executive director of the Faith & Media Initiative, said, “Religion can feel scary to talk about — like politics — so it creates the illusion that it's a small group. That makes it easy for filmmakers to oversimplify it or not give it much thought, instead of recognizing how valuable faith storytelling can be when it's done well.”  Close And that's The Worldview on this Thursday, February 12th, in the year of our Lord 2026. Follow us on X or subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com.  I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

What if improving peptides for gut health was one of the missing pieces in helping your body feel more stable and supported? When you live with Hashimoto's, it can feel like you are constantly chasing symptoms. Fatigue, brain fog, food reactions, and unpredictable energy can make daily life harder than it should be. One major piece that often gets overlooked is how much your gut influences your immune system, your energy, and your ability to feel like yourself again. This episode explains why gut function matters so much and why supporting gut signaling may be a key step in moving forward. In this episode, you will learn: Why gut health is a major root cause factor in Hashimoto's How leaky gut can affect immune balance and symptoms How peptide signaling supports gut repair, regulation, and restoration How to tell your body to MAKE more peptides. Naturally. If you are ready to understand how gut repair fits into your bigger Hashimoto's picture, press play on this episode now.   Mentioned:  Healthy Edge Stack: https://estheryunkin.lifevantage.com/us-en/shop/healthy-edge-stack  Hashimoto's Root Cause Reset: https://healthwithhashimotos.com/book-now/ Health with Hashimoto's community on Skool: https://www.skool.com/health-with-hashimotos/about   Find all links on my resource page: https://healthwithhashimotos.com/resources/   ABOUT THE PODCAST & ESTHER: The Health with Hashimoto's podcast will help you explore the root causes of your autoimmune condition and discover holistic solutions to address your Hashimoto's thyroiditis. It is hosted by Esther Yunkin, a registered nurse, holistic health educator, and Hashimoto's warrior.   This podcast is for informational and educational purposes. Please discuss any questions or concerns with your healthcare professional. These statements have not been evaluated by the Food and Drug Administration. Products mentioned are not intended to diagnose, treat, cure or prevent any disease.

Fatigue, joint pain, brain fog, hair loss, anxiety… and your doctor says your labs are fine. What if your breast implants are the missing piece? In this episode, I join Brandi to explore the truth about Breast Implant Illness (BII) and share essential information to help you understand what to do about this growing health concern. What We Cover:What breast implant illness (BII) actually is and why it's not "in your head"The top reported symptoms of BII to look out for How breast implants increase your risk of autoimmune diseasesMechanisms of breast implant illness like the biofilm theoryThe "rain barrel effect": how long-term immune dysregulation leads to gut issues, nutrient deficiencies, and toxic overloadTimeline of symptom onset with BIIHow to safely remove implantsWhy explant is just the beginning and the next steps to true healingSponsors:EQUIP Prime Protein: https://www.equipfoods.com/NHR15 Save 15% off with code: NHR15Connect with Rachel:Free Health Consultation with Rachel: ⁠⁠⁠⁠⁠⁠⁠https://www.naturalhealthrising.net/health-consultation⁠⁠⁠⁠⁠⁠⁠Free Webinar to Heal Your Autoimmune & Mystery Symptoms: ⁠⁠⁠⁠⁠⁠⁠https://www.naturalhealthrising.net/webinar⁠⁠⁠⁠⁠⁠⁠Join the Natural Health Rising community to heal naturally: ⁠https://www.skool.com/natural-health-rising-6209/about?ref=77c29ce69cbf4fb2be0865f18fea6bcc⁠Website: ⁠⁠⁠⁠⁠⁠⁠https://naturalhealthrising.com/⁠⁠⁠⁠⁠⁠⁠Support this podcast: ⁠⁠⁠⁠⁠⁠⁠https://anchor.fm/rachel-smith11/support⁠⁠⁠⁠Breast Explant References:[1] Ferreira, S., Barros, A. S., & Marques, M. (2025). Breast Implant Illness: Symptoms, Outcomes with Explantation and Potential Etiologies—A Systematic Review and Meta-analysis. Aesthetic Plastic Surgery, 49(23), 6600–6620.[2] U.S. Food and Drug Administration. (2025, February 6). Medical Device Reports of Systemic Symptoms in Women with Breast Implants.[3] Suh, L. J., Khan, I., Kelley-Patteson, C., Mohan, G., Hassanein, A. H., & Sinha, M. (2022). Breast Implant-Associated Immunological Disorders. Journal of Immunology Research, 2022, 8536149.[4] Watad, A., Rosenberg, V., Tiosano, S., et al. (2018). Silicone breast implants and the risk of autoimmune/rheumatic disorders: a real-world analysis. International Journal of Epidemiology, 47(6), 1846-1854.[5] Adams, W. P., Jr., & Deva, A. K. (2020). Surgical Best Practices: 14-Point Plan. Sientra.[6] DeCesaris, L. (2022, September 22). A Functional Medicine Approach to Breast Implant Illness: BII. Rupa Health.[7] Dreyfuss, D. (n.d.). 8 Tips for a Quick Breast Implant Removal Recovery. Dreyfuss Plastic Surgery.

"I will say that QAnon was right and I was wrong." — Pepper CulpepperFrom Bannon and Trump to Summers, Gates, Blavatnik and Chomsky, the Epstein scandal has revealed elites of all ideological stripes behaving shamefully together. The Oxford political scientist Pepper Culpepper argues this is exactly the kind of corporate scandal that can save democracy—not despite its ugliness, but because of it. His new co-authored book, Billionaire Backlash, shows how scandals activate "latent opinion," bringing long-simmering public concerns to the surface and triggering society-wide demand for regulation. We discuss why Cambridge Analytica led to California privacy law, how Samsung's bribery scandal sparked Korea's Candlelight Protests, and why China's authoritarian approach to corporate malfeasance actually undermines trust.Culpepper, himself the Blavatnik Professor of Government at Oxford's Blavatnik School, acknowledges an uncomfortable truth. "I would say that QAnon was right," he admits, "and I was wrong." The specifics might have been fantasy, but the underlying suspicion about elite corruption was justified. And policy entrepreneurs—obsessive individuals who channel public outrage into actual legislation—matter more than we think. For Culpepper, billionaire backlash isn't a threat to democracy—it might actually be what saves it.About the GuestPepper Culpepper is Vice Dean of the Blavatnik School of Government at the University of Oxford. He is the co-author, with Taeku Lee of Harvard, of Billionaire Backlash: The Age of Corporate Scandal and How It Could Save Democracy (2026).ReferencesScandals discussed:●      The Epstein scandal revealed that elites across politics, finance, and academia were connected to Jeffrey Epstein's network of abuse—vindicating populist suspicions that "the system is broken."●      Cambridge Analytica (2018) exposed how Facebook leaked data on 90 million users, leading to the Digital Markets Act and Digital Services Act in the EU, and California's privacy regulations.●      The Samsung bribery scandal in South Korea led to the Candlelight Protests and President Park Geun-hye's resignation, demonstrating how corporate scandals can strengthen civil society.●      The 2008 Chinese milk scandal killed six infants due to melamine contamination; the government's cover-up during the Beijing Olympics destroyed public trust in domestic food safety.●      Volkswagen's Dieselgate scandal showed how companies cheat on regulations, bringing latent concerns about corporate behavior to the surface.Policy entrepreneurs mentioned:●      Carl Levin was a US Senator from Michigan who shepherded the Goldman Sachs hearings and contributed to the Dodd-Frank Act.●      Margrethe Vestager served as EU Competition Commissioner and pushed for the Digital Markets Act and Digital Services Act.●      Max Schrems is an Austrian privacy activist who, as a student, discovered Facebook retained his deleted messages and eventually brought down the US-EU data transfer agreement.●      Alastair Mactaggart is a California property developer who pushed through the state's privacy regulations when federal action proved impossible.●      Zhao Lianhai was a Chinese activist who tried to organize parents after the 2008 milk scandal; the government arrested and imprisoned him.Concepts discussed:●      Latent opinion refers to concerns people hold in the back of their minds that aren't front-of-mind until a scandal brings them to the surface.●      The Thermidor reference is to the French Revolutionary period when the radical Jacobins were overthrown—Culpepper suggests a controlled version might benefit democracy.●      The muckrakers were Progressive Era journalists whose exposés led to reforms like the Food and Drug Administration.Also mentioned:●      Michael Sandel is a Harvard political philosopher known for arguing that "there shouldn't be a price on everything."●      Patrick Radden Keefe wrote Empire of Pain, the definitive account of the Sackler family and the opioid epidemic.●      Lee Jae-yong is the heir apparent to Samsung, implicated in the bribery scandal.●      Parasite, Squid Game, and No Other Choice are Korean cultural works that critique the country's relationship with its conglomerates.About Keen On AmericaNobody asks more awkward questions than the Anglo-American writer and filmmaker Andrew Keen. In Keen On America, Andrew brings his pointed Transatlantic wit to making sense of the United States—hosting daily interviews about the history and future of this now venerable Republic. With nearly 2,800 episodes since the show launched on TechCrunch in 2010, Keen On America is the most prolific intellectual interview show in the history of podcasting.WebsiteSubstackYouTubeApple PodcastsSpotifyChapters:(00:00) - (00:22) - The Epstein opportunity (01:21) - Elite overreach exposed (03:12) - Scandals without partisan charge (05:04) - The Vice Dean's credibility problem (06:21) - Latent opinion explained (09:39) - Is there anything wrong with being a billionaire? (11:47) - American vs. European scandals (14:48) - Saving democracy vs. saving capitalism (17:05) - Corporate scandals and economic vitality (18:33) - Policy entrepreneurs: Carl Levin and Margrethe Vestager (19:54...

Silver, Gold and Crypto (oh my) Hang on – Wild ride here Superbowl, Olympics- Wait until you hear about the CAPex spending! Shakeup in Dietville PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Interactive Brokers  Warm-Up - Silver, Gold and Crypto (oh my) - Need a stock for CTP - Hang on - Wild ride here - Superbowl, Olympics- Wait until you hear about the CAPex spending! - Shakeup in Dietville Markets - Massive moved during the week - - Bitcoin clipped $60k before rebounding - DJIA tops 50,000 for the first time - Wait until you hear about the CAPex spending! - CAT == 1,100 points on the DJIA in 2026 Superbowl and Superbowl ads - Game review - Any ad stick out? - $10M per ad this year - Half Time with Bad Bunny? - Anthropic busting on OpenAi Last Week! - Massive moved - quick calc showed that about $1T was wiped from market caps in the sell-off, particularly in tech names. - HOWEVER - Friday alone is estimated to have added $1.5T to market cap AI Ripping Through - Plenty of names getting cooked over AI announcements - First it was the software companies - Now there are names in legal and finance that got clocked - Today - Altruist.ai can do tax planning and that hurt companies in financial space Earnings Season Update - Reporting so far: 59% of S&P 500 companies have reported Q4 2025 results. - Beat rate: 76% have topped EPS estimates (vs. 5-yr average: 78% (slightly lower) vs. 10-yr average: 76% (in line) - Magnitude of beats (aggregate): earnings are 7.6% above estimates vs. 5-yr average: 7.7% (about the same) vs. 10-yr average: 7.0% (a bit better) - Nothing great,  like Goldilocks Earnings Highlights - Palantir (PLTR): Reported strong Q4 results early in the week , beating estimates with revenue ~$1.41B (vs. ~$1.33B expected) and EPS $0.25 (vs. $0.23). Guidance for 2026 was upbeat (~61% revenue growth). Shares rallied sharply initially (~7–11% post-earnings), but gave back some gains amid broader tech volatility (e.g., down ~11–22% in parts of the week from peaks). - AMD: Reported mid-week, beating EPS (~$1.53 vs. lower expectations) with solid data center growth (~39%). However, Q1 guidance disappointed relative to high expectations in the AI chip space. Shares sank dramatically — down ~15–17% the next day, with some reports noting up to 20%+ drops at points, contributing to broader chip sector pressure. - Alphabet (GOOGL/GOOG): Reported beating on revenue (~$113.8B) and EPS (~$2.82), with strong core performance. But capex guidance for 2026 ($175–$185B, roughly double prior levels) sparked AI spending worries. Shares dipped post-earnings (down ~0.5–5% initially, flat to lower the next day, with some volatility pulling it below key moving averages). - Amazon (AMZN): Reported after hours on February 5, with mixed results — EPS ~$1.95 (narrow miss vs. ~$1.97 expected), but solid overall. The big negative was a surprise $200B capex forecast for 2026 (well above expectations), tied to AI/cloud buildout. Shares plunged sharply — down ~7–10% in after-hours/extended trading, with Friday moves around -5–8% in some sessions. Recent Tech CAPEX announcements - Amazon (AMZN) — Guided to approximately $200 billion in capex for 2026 (a massive jump from ~$125–131 billion in 2025, with ~80% likely AI-related per analyst commentary). This was the largest single-company figure and a major surprise, contributing heavily to the week's "wild" reactions. - Alphabet (GOOGL/GOOG) — Guided to $175–185 billion in capex for 2026 (roughly double the $91 billion spent in 2025, far above analyst expectations of ~$115–119 billion). Emphasis was on AI compute capacity, servers, data centers, and networking to meet demand for Gemini and cloud services. - Meta Platforms (META) — Guidance from late January (but heavily discussed last week): $115–135 billion for 2026 (up significantly from ~$70–72 billion in 2025, potentially an ~87% increase). - Microsoft (MSFT) — No new full explicit 2026 guidance in early February (fiscal year runs July–June), but recent quarterly run-rate and analyst projections put it around $97–145 billion (with some sources citing ~$105 billion or higher based on Q2 spending trends and signals of continued growth from prior levels of ~$88 billion in FY2025). ------!!!!Combined 2026 capex projected at $635–665 billion (low/high ends) or up to $650–700 billion in some reports — a ~60–74% increase from their collective ~$381 billion in 2025. Market Reaction from all of this.... - Markets were a bit spooked on the Anthropic announcement earlier in the week - software sold off and set a sour mood - Microsoft dumped pretty hard as the amount of spend was higher than anticipated, especially with some slower growth in Azure. - Amazon took a beating on the increased spend they anticipate *(extra by $50B) - BUT: Friday markets rallied as there was realization that the $200B spend by Amazon would seep into the economy and fuel infrastructure spending along with chips, tech etc. Other Earnings of Interest -  Reddit reported fourth-quarter earnings on Thursday in which the social media company beat on the top and bottom lines. - The company said it expects first-quarter sales to come in the range of $595 million to $605 million, which is higher than Wall Street expectations of $577 million. - Reddit also announced a $1 billion share repurchase program. - Reddit gets about $250 million a year from OpenAi and Google to have your data for training their LLMs While we are on the subject - Friday, DJIA hit 50,000 - first time ever! - Up 1,200 point of which approx 350 was from caterpillar and 280 was from Goldman Sachs Hats off to WalMart - Walmart Inc. shares pushed its market capitalization past $1 trillion on Tuesday for the first time ever| - Big transformation over the pst year - Walmart has maintained its appeal to households looking for value, its online offerings are drawing new, wealthier shoppers seeking convenience. Google Bond Offering - Issuing several tranches of bonds, denominated in Stirling - one as long as 100 years - Would you buy that? - The Google parent is set to raise $20 billion from a US dollar bond offering on Monday — more than the $15 billion initially expected — and is also pitching investors on what would be its first ever offerings in Switzerland and the UK. - The latter would include a rare sale of 100-year bonds, the first time a tech company has tried such an offering since the dotcom frenzy of the late 1990s Fat Profits in Dietville - Really interesting sequence of events happening... - Hims launches compounded pill at prices as low as $49 per month - Analysts cite questions on efficacy, legality of pill - Hims' move shifts focus from Novo's strong Wegovy pill launch - Broader obesity market whipsawed as pricing pressure rises THEN.. - Hims and Hers Health shares dive 14% after hours on Friday (Down 25% on Monday) - FDA cites concerns over quality, safety, federal law - The U.S. Food and Drug Administration said on Friday it would take action against telehealth provider Hims & Hers, for its $49 weight-loss pill, including restricting access to the drug's ingredients and referring the company to the Department of Justice for potential violations of federal law. AND.... - Eli Lilly last Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. - The pharmaceutical giant anticipates its 2026 revenue will come in between $80 billion and $83 billion. Analysts expected revenue of $77.62 billion, according to LSEG. - Meanwhile, NOVO had a really bad outlook that took the shares down 13% after the report. Japan Markets Soar - Japanese stocks jumped to a record high Monday, leading gains in the region after Prime Minister Sanae Takaichi won a landmark election victory. - The ruling Liberal Democratic Party captured a two-thirds supermajority in the 465-seat lower house, public broadcaster NHK reported. - Japan's Nikkei 225 jumped past 57,000 for the first time before paring gains to close 3.9% higher at 56,363.94, while the Topix also notched a record high, closing at 3,783.94, up 2.3%. Employment Report? - Government shutdown is forcing them to postpone again (Which is dumb) - Number due this Wednesday - Maybe because of this:U.S. employers announced 108,435 layoffs for the month, up 118% from the same period a year ago and 205% from December 2025. The total marked the highest for any January since 2009. - At the same time, companies announced just 5,306 new hires, also the lowest January since 2009, which is when Challenger, Gray & Christmas began tracking such data. - Also, job openings fell sharply in December to 6.54 million, to their lowest since September 2020. - Available jobs are down by more than 900,000 just since October. - NO! Ai and advancements in tech have noting to do with this! NO NO NO M&A - Texas Instruments Inc. has reached an agreement to buy Silicon Laboratories Inc. for about $7.5 billion, deepening its exposure to several markets for chips. - Silicon Labs investors will receive $231 in cash for each share of the company's common stock and the transaction is expected to close in the first half of 2027. - The transaction still needs to win approval by investors in Silicon Labs and shares of Silicon Labs surged by 51% to $206.48 after the announcement. Inflation - This helps - PepsiCo (PEP.O), opens new tab will cut prices on core brands such as Lay's and Doritos by up to 15% following a consumer backlash against several previous price hikes, the snacks and beverage maker said on Tuesday after it topped fourth-quarter results. Miran - Moving - Federal Reserve Governor Stephen Miran is leaving his post as chair of the Council of Economic Advisers, CNBC has confirmed. - He joined the CEA in January 2025, but had been on leave from that post since last September when he filled the unexpired term of former Fed Governor Adriana Kugler.- He reamins on Fed board No Biggie???? - There are some astonishing cased being reported of Bad AI in the operating room - JNJ's TruDi Navigation System - Since AI was added to the device, the FDA has received unconfirmed reports of at least 100 malfunctions and adverse events. - At least 10 people were injured between late 2021 and November 2025, according to the reports. Most allegedly involved errors in which the TruDi Navigation System misinformed surgeons about the location of their instruments while they were using them inside patients' heads during operations. - Cerebrospinal fluid reportedly leaked from one patient's nose. In another reported case, a surgeon mistakenly punctured the base of a patient's skull. In two other cases, patients each allegedly suffered strokes after a major artery was accidentally injured. Cuba - The main airport has putt out a bulletin that they are out of Jet Fuel - Blackouts and lack of other fuels are creating big problems - No airlines have stopped running at this point, but many will as they cannot refuel - This is a bigger problem for cargo planes (supplies) that may not be able to risk flying to Cuba as they will not be able to get out. Love the Show? Then how about a Donation? ANNOUNCING THE WINNER OF THE THE CLOSEST TO THE PIN CUP 2025 Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt!     FED AND CRYPTO LIMERICKS   See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Your CANCER Diagnosis Isn't Your Fault (And Why That Matters): A Stage 4 Cancer Survivor's Truth About Energy and Healing with Maria Kang  What if everything you think you know about cancer and healing is actually backwards? Maria Kang has lived a life that defies conventional narratives. She's the "No Excuses Mom" who challenged the fitness industry…and then she got stage 4 cancer while doing everything "right." But instead of following the standard playbook, she made a choice that shocked everyone around her and in that, discovered that cancer wasn't her enemy - it was her greatest teacher. This is not your typical cancer survival story. In this conversation, Maria walks us through her journey from the moment of diagnosis through the stunning realization that cancer, autoimmune disease, and chronic illness emerge from an energetic state of chronic self-betrayal. She shares why she resisted chemotherapy, what happened when the tumor shrank after gratitude practice, why cancer returned, and what truly shifted when she finally surrendered. More importantly, she reveals what this teaches every woman about people-pleasing, boundaries, inner authority, and the cost of abandoning yourself. Whether or not you're facing a cancer diagnosis, this episode will change how you listen to your body. Maria's recent book, Sacred Becoming, documents her full transformation. And what Natalie discovered while reading it is that this isn't just a cancer story, it's a blueprint for remembering who you actually are underneath all the conditioning. Midlife women are in a health crisis not just about food or fitness. It's about chronic disconnection from your own inner knowing. It's about people-pleasing patterns that literally make your body sick. It's about forgotten boundaries and abandoned dreams. Maria's story shows what happens when those patterns escalate to cancer. And more importantly, it shows what becomes possible when you finally listen to your body and remember who you actually are.   Episode Links:  Maria's new book: Sacred Becoming https://www.sacredbecomingbooks.com/products/sacred-becoming-book Past Episode - 401: The GIFT of Cancer with Maria Kang https://podcasts.apple.com/us/podcast/401-the-gift-of-cancer-with-maria-kang/id1436973433?i=1000673961700    Catch the full episode on YOUTUBE HERE: https://bit.ly/MidlifeConversationsYouTube    Learn More About Maria Kang Instagram ➜ https://www.instagram.com/mariakangfitness  Website ➜  https://www.mariakang.com/  Book ➜  https://www.sacredbecomingbooks.com/products/sacred-becoming-book  Thank you to our show sponsors! QUANTUM UPGRADE: Try Quantum Upgrade completely free for 15 days—no credit card required. Use code NATALIEJILL at checkout on https://quantumupgrade.io/ TIMELINE:  Timeline is offering 20% off your order of Mitopure! Go to https://timeline.com/NATALIEJILL  Free Gifts for being a listener of Midlife Conversations! Mastering the Midlife Midsection Guide: https://theflatbellyguide.com/ Age Optimizing and Supplement Guide: https://ageoptimizer.com   Connect with me on social media! Instagram: www.Instagram.com/Nataliejllfit Facebook: www.Facebook.com/Nataliejillfit   For advertising inquiries: https://www.category3.ca/  Disclaimer: Information provided in the Midlife Conversations podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before making any changes to your current regimen.  Information provided in this podcast and the use of any products or services related to this podcast does not create a client-patient relationship between you and the host of Midlife Conversations or you and any doctor or provider interviewed and featured on this show. Information and statements may have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease. Advertising Disclosure: Some episodes of Midlife Conversations may be sponsored by products or services discussed during the show. The host may receive compensation for such advertisements or if you purchase products through affiliate links. Opinions expressed about products or services are those of the host and/or guests and do not necessarily reflect the views of any sponsor. Sponsorship does not imply endorsement of any product or service by healthcare professionals featured on this podcast.

Why calorie counting fails — and why hunger, not willpower, drives eating behavior. Episode #244

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: T1D in the Olympics & Superbowl, Trump RX goes live, Ozempic pill available soon, tech updates from Medtronic, Beta Bionics, Eversense 365 and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: We are just over one week from our first Moms' Night Out event of the year. While the plans are all set – the speakers, the vendors, the raffles and the fun is ready to go, it's always amazing how many people hear of these event last minute. That's fine, they're welcome! But if you're thinking of attending a future event – registration is open for We're going to Nashville next March 6-7 and Detroit in September – no need to wait. And we've got Club 1921 events for health care professionals and patient leaders in 6 cities this year! All the info is over at diabetes-connetionss.com events/   Okay.. our top story this week: XX Gotta be a quick shout out to some incredible T1D athletes – we had TWO in the super bowl this past weekend – Chad Muma of the New England Patriots and Logan Brown of the Seattle Seahawks AND there are at least two athletes with type 1 competing at the Winter Olympics. Hannah Schmidt competes in ski cross for Canada – she was diagnosed with Type 1 diabetes at age 12 years old.  Anna FarnSchadt Fernstäd a Czech skeleton racer diagnosed in 2022 after she'd already been to several Olympics. We wish them all the best!   https://english.radio.cz/skeleton-racer-anna-fernstadtova-overcoming-adversity-headfirst-down-ice-8876699 XX The government website TrumpRx.gov is live..  the website does not sell prescription drugs. Instead, it allows people to look up their drugs and then navigate to buy them elsewhere, either from a major drug company or a pharmacy. The 43 drugs listed on the site have prices ranging from $3 to over $5,500. TrumpRx does include warnings that the site may not be the best option to save money on prescriptions. Each product page advises: "If you have insurance, check your co-pay first — it may be even lower." For now, the website says its prices are for people paying with their own money, rather than going through insurance. The only insulin listed right now is Lilly's insulin lispro – and it's the same price as you'd find through Illy's insulin value program. I looked up diabetes meds.. For example, if you have an insurance co-pay of $25 a month for Farxiga, a drug often used for diabetes, you would be paying $182 on TrumpRx. As you can imagine, though ,this is complicated and as with most of our healthcare system, it may be good in some cases and not much help in other.  I'd suggest calling your local pharmacist or checking with your human resource dept. https://www.nytimes.com/2026/02/06/health/trumprx-prescription-drug-prices-consumers.html XX Novo Nordisk will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. The company said the U.S. Food and Drug Administration has approved Ozempic tablets in three different doses. Novo says The new Ozempic name is intended to help patients and health care professionals more easily recognize the available treatment options for type 2 diabetes Semaglutide tablets have been available under the brand name Rybelsus Ruh BELL sis for diabetes since 2019 but with different dosing. The pill is also approved to reduce the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk for these events. The FDA had approved the new doses based on a bioequivalence study and the clinical trial data for Rybelsus, Novo said. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-launch-ozempic-pill-diabetes-second-quarter-this-year-2026-02-04/ XX https://www.contemporarypediatrics.com/view/early-screening-for-type-1-diabetes-found-effective-in-children XX Possible new way to identify and track the progress of type 1 diabetes before clinical onset. A recent study published in Science Advances described the application of subcutaneous microporous scaffolds. These are inserted and have been shown to  identify changes in cancer, multiple sclerosis, and T1D by capturing changes of immune cells over the course of a disease. This is a proof of concept study in mice.. so very early days. https://www.news-medical.net/news/20260204/Implantable-immune-scaffold-predicts-type-1-diabetes-weeks-before-symptoms.aspx XX A large global genetics study shows that many key drivers of Type 2 diabetes operate outside the bloodstream. In a major international project led in part by the University of Massachusetts Amherst and Helmholtz Munich in Germany, researchers linked hundreds of genes and proteins to the disease. The work, published in Nature Metabolism, points to a key challenge in diabetes research: the biology behind rising blood sugar does not play out the same way in every part of the body. It also shows why including people from many backgrounds matters, since genetic clues that stand out in one population may be faint or invisible in another. Huge study, 2.5 million people worldwide comparing patterns across seven tissues tied to diabetes and four global ancestry groups, then asked a simple question: what do you miss if you only measure blood? Across the seven tissues, the researchers found causal evidence pointing to 676 genes. Yet overlap with blood was limited: only 18% of genes with a causal effect in a primary diabetes tissue, such as the pancreas, showed a matching signal in blood. At the same time, 85% of genetic effects observed in diabetes-relevant tissues were completely absent from blood-based analyses. The findings lay out a roadmap for future research aimed at understanding the biological pathways underlying Type 2 diabetes and developing more effective treatments. https://scitechdaily.com/massive-global-study-rewrites-the-biology-of-type-2-diabetes/ XX Express Scripts settled the U.S. Federal Trade Commission's claims its insulin pricing practices violated antitrust and consumer protection laws, and agreed to changes aimed at lowering costs for patients, insurers and small pharmacies The settlement, first reported by Reuters, fits with that goal, and allows the FTC to pare down a case brought by the former Biden administration against Cigna's Express Scripts, UnitedHealth Group Inc's (UNH.N), Optum unit and CVS Health Corp's (CVS.N), CVS Caremark. The case against Optum and Caremark is ongoing. Pharmacy benefit managers, which set how drugs are covered by health insurance, have faced a decade of scrutiny from regulators and lawmakers over pricing practices. While the industry has already made reforms, the settlement gives the FTC power to enforce broader changes at Express Scripts. The 10-year agreement restricts Express Scripts' ability to engage in practices critics say contribute to high costs, like pocketing rebate payments from drugmakers based on the list price of drugs. The FTC estimates the agreement could save patients as much as $7 billion over a decade. https://www.reuters.com/world/cigna-settles-ftc-insulin-case-commits-overhauling-drug-pricing-2026-02-04/ XX Audio? Congress has passed bipartisan legislation to extend and strengthen the Special Diabetes Program (SDP), a cornerstone of Federal investment in type 1 diabetes (T1D) research. The President signed the legislation and it is now law. Extends the SDP through December 31, 2026, and increases funding from $160 million to $200 million annually. Strengthens overall funding for the National Institutes of Health (NIH) by $415 million. Increases diabetes research funding at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) by $10 million. Created by Congress and administered by the NIH, the SDP has contributed nearly $3.6 billion to T1D research and has played a role in nearly every major breakthrough in the field. A recent study conducted by Avalere Health shows that of the nearly 3.6 billion invested into the SDP by Congress since the establishment of the program, the Federal Government has realized $50 billion in healthcare savings through improved health outcomes from the use of SDP driven therapies and devices https://www.breakthrought1d.org/news-and-updates/congress-passes-bipartisan-extension-of-the-special-diabetes-program-securing-critical-t1d-research-funding/ XX Dexcom is rolling out what they're calling AI-enabled enhancements to Stelo, further transforming how users track and understand their glucose health. Expanded Smart Food Logging including a comprehensive nutrition database of more than 1M meals that provides a breakdown of calories, carbohydrates, protein, fat, dietary fibers, and more. More ways to meal track including text search, barcode scanning or taking a photo of the meal, creating a seamless and intuitive meal tracking solution. A redesigned Daily Insights feature which will introduce a new interface with more personalized recommendations. The newest features will launch nationwide in the coming weeks.  XX Beta Bionics has received a warning letter from the Food and Drug Administration following an inspection last year, the company disclosed on Friday. The diabetes technology company said in a securities filing that the warning letter concerns non-conformities with the company's quality management system, medical device reporting, and correction and removals. The warning letter has not yet been posted by the FDA.   The company said in the filing that it has already taken actions to improve the processes described in the warning letter, and it is working on a written response to the FDA.   The firm does not expect the warning letter to affect the planned launch of a new insulin patch pump by the end of 2027. Beta Bionics unveiled a prototype of the device, called Mint, last year at the American Diabetes Association's Scientific Sessions. The company also does not expect the warning letter to affect its financial results. https://www.medtechdive.com/news/beta-bionics-receives-fda-warning-letter/811140/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue%3A+2026-02-04+MedTech+Dive+%5Bissue%3A81423%5D&utm_term=MedTech+Dive&fbclid=IwY2xjawPwhDZleHRuA2FlbQIxMABicmlkETFaUUcyYmNQWldjZ2xudElic3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHouF8M3IstTyslPRgeHWUWVVdOAGOtzPWt_yNFcj9eYruqSPz3e86Iwcbpt8_aem_7q4D97vJVjHKfEwvoyUpgw XX Sequel Med Tech is reviewing co-founder Dean Kamen's ties to Jeffrey Epstein after recently released documents revealed new details about the longstanding relationship between the two men. The documents show that Kamen visited Epstein's island, and remained in contact with him for years after Epstein was convicted of sex crimes involving minors. Kamen has not been accused of any wrongdoing. In a statement, Sequel Med Tech said the Manchester-based company is aware of the documents pertaining to Kamen and – quote - "Sequel's Board of Directors has unanimously decided to engage an external law firm to review these disclosures and provide recommendations aligned with our mission to serve people living with diabetes," Kamen has not issued a statement regarding his reported connection to Epstein.   https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.nbcboston.com/news/local/nh-inventor-placed-on-leave-after-epstein-messages-surface-report-says/3888569/ XX Abbot reports 860 serious injuries linked to the recall of some of its glucose monitoring sensors. We told you about this recall late last year, these numbers are an FDA update.     Abbott said the sensors can provide incorrect glucose readings over extended periods, which could lead to users making dangerous treatment decisions, including eating excessive carbohydrates along with skipping or delaying insulin doses, potentially leading to serious health risks. The company said it has identified and resolved the cause of the issue, which relates to one production line among several that make Libre 3 and Libre 3 Plus sensors.   https://www.reuters.com/business/healthcare-pharmaceuticals/abbott-recalls-glucose-sensors-after-seven-deaths-linked-faulty-readings-2026-02-04/ XX Updates from Medtronic & Senseonics – and a first from Nick Jonas.. right after this..   I'm excited to share that the FDA has cleared the MiniMed 780G system with the Instinct sensor, made by Abbott, for people with type 2 diabetes.  Medicare has also now approved coverage for the Instinct sensor for use with the MiniMed 780G system. This clearance and expanded coverage mean more people will have access to pairing our most advanced automated insulin delivery technology with the Instinct sensor, that offers a smaller, 15-day sensor experience.  They're also launching the MiniMed 780G system Pump Evaluation Program.  This program gives individuals living with diabetes the ability to try the full MiniMed 780G system at no cost for 30 days.† This includes the pump, the sensor of their choice, one month of infusion sets and reservoirs, everything but the insulin. They'll contact your doctor for you to get a prescription and get the process rolling. https://www.medtronicdiabetes.com/pump-evaluation-program XX Senseonics announced today that its Eversense 365 continuous glucose monitor (CGM) system received CE mark approval – that's European clearance.  This comes on the heels of the launch of Eversense 365 with Sequel Med Tech's twiist pump, marking the first pump integration for the CGM. Senseonics plans to launch Eversense 365 in Germany, Italy, Spain and Sweden in the coming months. Meanwhile, Senseonics continues to work toward an FDA investigational device exemption (IDE) submission for its next-generation Gemini transmitter-less CGM by the end of this year. https://www.drugdeliverybusiness.com/senseonics-ce-mark-eversense-365-cgm/ XX A huge shout out to Dr. Emily Blum, who just accomplished riding 100 miles in Antarctica for Breakthrough T1D! Despite having no direct connection to Type 1 Diabetes, Emily has been riding and fundraising for BreakthroughT1D for 10 years now. She is an integral part of the Georgia Ride team, training and riding many miles, and most importantly has raised tens of thousands of dollars to support the cause of ridding the world of T1D. She is surgeon and deeply involved with medical innovation, with an incredibly busy schedule, but jumped at the chance to take on the challenge of riding a century on every continent. Having already completed North America, Europe, Australia, Asia, and now Antarctica, only Africa and South America remain. Emily rides on and continues to be an inspiration to everyone who meets her. XX   https://diabetes-connections.com/t1d-connection-and-people-magazine-elise-zach-share-their-story/ XX Nick Jonas's becomes the first artist ever to wear a CGM on an album cover - new upcoming solo album Sunday Best, releasing Feb. 6.  The release says: This marks a powerful step forward in normalizing diabetes and raising awareness for the condition on a global scale. This moment adds to the growing visibility of diabetes in pop culture, alongside milestones like a Type 1 diabetes Barbie and Pixar characters wearing diabetes technology.

A.M. Edition for Feb. 9. The latest revelations from the Epstein files bring down the top aide to Britain's Prime Minister. Will Keir Starmer be next? WSJ U.K. correspondent Max Colchester weighs in. Plus, Novo Nordisk shares are rallying after the U.S. Food and Drug Administration threatened to restrict access to the ingredients needed for knockoffs of popular GLP-1 medicines like WeGovy. And SpaceX delays its Mars plans to focus on the Moon instead. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Hey Mama,  Last week we talked about the importance of drinking water, the damage dehydration can do to your body, and all the amazing benefits of good hydration, not only for your physical body, but also for your ability to manage stress. However, how much water we drink each day can quickly feel like a chore, or one more thing we have to keep track of as busy moms. The truth is, there are ways to build your water consumption into your daily routine, no matter how full it is. Plus, up-leveling your water with essential oils can help you have all day energy and focus for a busy mom. Join me today to learn how to incorporate more water in your day through three simple and stackable habits to help you drink more water for all day energy and focus as a busy mom.   Link to the essential oils I use in my water: https://bit.ly/oilsforwater    For His Glory, Christen   I would love to hear from you!  >>Leave a Review >>Connect with me:   Sign Up for Manage In The Moment Coaching Call: https://bit.ly/ManageStressInTheMoment   Email me : naturalwellnessforbusymoms@gmail.com  Sign Up to Become an Insider: https://bit.ly/naturalwellnessinsider  Join Our FREE Facebook Community:https://www.facebook.com/groups/1789472588229094  >>Find Related Products Here: https://bit.ly/m/Natural-Wellness-for-Busy-Moms  >> These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. >>I make a small commission when using the links above to purchase items.